Zhou Minfeng, Niu Huifang, Lu Damin, Zhang Haiming, Luo Dan, Yu Zhaomin, Huang Guichen, Li Jinxiao, Xiong Chutong, Tang Qian, Zhang Hongxing, Liang Fengxia, Chen Rui
Department of Integrative Chinese and Western Medicine, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, 1277 Liberation Avenue, 430022, Wuhan City, China.
Jianghan University School of Medicine, 8 Triangle Lake Road, 430056, Wuhan City, China; Jianghan University Institute of Acupuncture and Moxibustion, 8 Triangle Lake Road, 430056, Wuhan City, China.
J Ethnopharmacol. 2025 Feb 10;338(Pt 1):118998. doi: 10.1016/j.jep.2024.118998. Epub 2024 Nov 1.
Wu Mei Wan (WMW) is a traditional Chinese herbal formula with a long-standing history in Chinese medicine, valued for its therapeutic properties. However, its potential anti-cancer effects, especially against colorectal cancer (CRC), have not been fully elucidated.
This study aims to investigate the effects of WMW on colorectal cancer stemness and to elucidate the underlying molecular mechanisms, focusing on the modulation of Sox9 expression via the JAK2/STAT3 signaling pathway.
WMW was prepared and analyzed using UPLC-MS to identify their main components. To study the therapeutic effects of WMW, AOM/DSS-induced CRC mouse models were established. A comprehensive suite of experimental techniques, including in vivo imaging, cell culture, transfection, CCK-8 assays, colony formation assays, wound healing assays, cell migration assays, Western blotting, dot blot analysis, RT-qPCR, immunohistochemistry, cell transcriptome sequencing, and gene set enrichment analysis, were utilized to explore the pharmacological effects and mechanisms of WMW.
WMW significantly inhibited CRC cell viability, proliferation, invasion, and migration in vitro. Mechanistically, WMW suppressed CRC stemness by downregulating Sox9 expression through the JAK2/STAT3 signaling pathway. Additionally, the regulation of methylation and demethylation mediated by TET1 and DNMT3a expression was directly associated with the JAK2/STAT3 pathway's modulation of Sox9 expression. In vivo, WMW treatment attenuated CRC progression and metastasis with minimal toxicity.
These findings suggest that WMW exerts potent anti-CRC stemness effects by regulating Sox9 via the JAK2/STAT3 signaling pathway, underscoring its potential as a promising therapeutic agent for CRC treatment.
乌梅丸(WMW)是一种在中医领域有着悠久历史的传统中药配方,因其治疗特性而受到重视。然而,其潜在的抗癌作用,尤其是对结直肠癌(CRC)的作用,尚未得到充分阐明。
本研究旨在探讨乌梅丸对结直肠癌干性的影响,并阐明其潜在的分子机制,重点关注通过JAK2/STAT3信号通路对Sox9表达的调节。
制备乌梅丸并采用超高效液相色谱-质谱联用(UPLC-MS)分析以鉴定其主要成分。为研究乌梅丸的治疗效果,建立了氧化偶氮甲烷/葡聚糖硫酸钠(AOM/DSS)诱导的结直肠癌小鼠模型。利用一系列综合实验技术,包括体内成像、细胞培养、转染、CCK-8测定、集落形成测定、伤口愈合测定、细胞迁移测定、蛋白质免疫印迹法、斑点印迹分析、逆转录定量聚合酶链反应(RT-qPCR)、免疫组织化学、细胞转录组测序和基因集富集分析,来探索乌梅丸的药理作用和机制。
乌梅丸在体外显著抑制结直肠癌细胞的活力、增殖、侵袭和迁移。机制上,乌梅丸通过JAK2/STAT3信号通路下调Sox9表达来抑制结直肠癌干性。此外,由TET1和DNMT3a表达介导的甲基化和去甲基化调节与JAK2/STAT3通路对Sox9表达的调节直接相关。在体内,乌梅丸治疗可减轻结直肠癌的进展和转移,且毒性最小。
这些发现表明,乌梅丸通过JAK2/STAT3信号通路调节Sox9发挥强大的抗结直肠癌干性作用,突出了其作为结直肠癌治疗有前景的治疗药物的潜力。